Feed LEGN
LE

Legend Biotech

LEGN · NASDAQ

$17.61 -0.79% (-$0.14)
1M -15.90%
Market Cap $3.26B
P/E Ratio -
Div. Yield -
ROE 8.70%
Piotroski F-Score Weak
3/9
Valuation
70 /100
Cheap
P/B 2.65x
P/S 2.56x
EV/FFO N/A
Growth
96 /100
Growing
Book val. growth 10.42%
Rev. growth 106.41%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 7.21%
Op. margin 4.42%
FCF margin 20.10%
Quality
9 /100
Poor
ROE 8.70%
ROA 5.23%
Asset turnover 0.73x
Debt
69 /100
Low
Current ratio 3.04x
Int. coverage -2.59x
Debt/Equity 0.23x
Stability
20 /100
Unstable
Rev. volatility 40.90%
EPS volatility 66.06%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about LEGN
Online

About the company

Legend Biotech Corporation (LEGN) is a global biotechnology company focused on developing and commercializing innovative therapeutic products in the field of hematology and oncology. The company is dedicated to researching new therapies for patients with leukemia and lymphoma, and its portfolio includes several potential drugs that have undergone clinical trials. Legend Biotech prioritizes high-quality research and development, collaborates with academic institutions and pharmaceutical partners, and stays abreast of the latest innovations in oncology. With increasing awareness of hematological disorders and a growing interest in new treatment modalities, investing in Legend Biotech Corporation (LEGN) shares may represent an interesting opportunity for investors interested in the biotechnology sector and seeking a company focused on innovative therapeutic products.

Sector

Healthcare

Industry

Biotechnology

CEO

Alan S. Bash

Employees

3,200

Headquarters

Somerset

Upcoming events

11 NOV

Earnings

Upcoming earnings report

51d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.